Exosomes have become one of the most heavily marketed products in regenerative medicine, often sold with claims that outpace the science. The honest picture is simple: the FDA has not approved any exosome product for any therapeutic use, and it has repeatedly warned patients about unapproved exosome treatments. This guide explains what exosomes are, how they differ from autologous stem cell therapy, and the questions to ask before any cell-based treatment.
0
exosome products approved by the FDA for any use
22+ years
combined clinical experience
12+
treatments & services offered
Exosomes are tiny particles that cells release as part of their normal communication. They carry proteins, lipids, and genetic material between cells, and in a research setting they are being studied for their signaling role. That research is real and interesting, but it is early. Exosomes are not stem cells, and no exosome product has been shown to work as a stand-in for cell therapy in approved, regulated use.
The U.S. Food and Drug Administration has issued a public safety alert warning that unapproved stem cell and exosome products can be unsafe, and it has been actively enforcing against clinics marketing unapproved biologics. The agency states plainly that there are no FDA-approved exosome products for any therapeutic use. A clinic that presents exosomes as an approved, proven treatment is not being straight with you.
“There are currently no FDA-approved exosome products for any therapeutic use. FDA continues to receive reports of patients who have experienced adverse reactions after receiving unapproved products marketed as exosomes or stem cells.”
At Aloha Stem Cell, the treatments we discuss are autologous, which means the material comes from your own body: bone marrow or fat tissue for cell-based therapy, and your own blood for platelet-rich plasma (PRP). Because the cells are your own, they are processed in the clinic for same-day delivery back to the treated area, not manufactured and shipped as a mystery product.
That distinction matters. A vial of 'exosomes' sold by a third-party supplier is a manufactured biologic with an unknown source and preparation history, and the FDA has warned about exactly these products. Autologous therapy starts from your own tissue, which you and your care team can trace from collection to injection.
A note from the clinic
If a clinic leads with a branded exosome injection and a long list of miracle claims, that is a red flag, not a selling point. At Aloha Stem Cell in Honolulu we would rather have the honest conversation: autologous cell therapy and PRP, clear evidence, and no products the FDA has flagged.
Our team is happy to listen to your story, answer your questions, and help you decide whether a consultation makes sense. There is no pressure and no obligation.
Keep reading
The FDA now lists Regenecyte, a cord blood stem cell product, among approved cellular therapies. It is a real milestone for blood stem cell transplant patients, and it is not a treatment for joint pain. Here is what the approval is, what it is not, and why it matters when you read stem cell news.
In September 2026 the FDA granted Fast Track status to an experimental cell therapy for ALS, and in August researchers presented new Phase 1/2 data on a stem cell therapy for Parkinson's. Both are real advances and both remain investigational. Here is the honest read.
A stem cell-derived islet therapy restored insulin production in early trials, with 10 of 12 patients insulin-independent at one year. Here is what the 2025-2026 results show, what the FDA has and has not done, and what it means for people with diabetes.
Book a consultation
Pick a time that works for you and our team will confirm your consultation. Questions first? Call us anytime at (808) 593-2525.